[Clinical trial of a new neuroleptic derivative: flupentixo flupentixol, in hypochondriac depression].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003863:Depression / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000431:Ethanol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006998:Hypochondriasis / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008620:Meprobamate / Q000627:therapeutic use; D008728:Methotrimeprazine / Q000627:therapeutic use; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D013881:Thioridazine / Q000627:therapeutic use; D013892:Thioxanthenes / Q000627:therapeutic use*; D013997:Time Factors; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D010879:Piperazines; D013892:Thioxanthenes; D014149:Tranquilizing Agents; D000431:Ethanol; D008728:Methotrimeprazine; D008620:Meprobamate; D013881:Thioridazine
Essai clinique d'un nouveau dérivé neuroleptique: flupentixol, dans les dépressions rypochondriaques.